<DOC>
	<DOCNO>NCT00157040</DOCNO>
	<brief_summary>The purpose study evaluate whether rAHF-PFM effective safe treatment child hemophilia A . The study consist 2 part . Part 1 study pharmacokinetic evaluation , Part 2 evaluation efficacy safety .</brief_summary>
	<brief_title>Study Pharmacokinetics , Efficacy , Safety Recombinant Protein-Free Factor VIII ( rAHF-PFM ) Pediatric Patients With Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Subject le 6 year age Severe moderatelysevere hemophilia A defined baseline factor VIII level &lt; = 2 % , document screening basis historical data ( e.g. , hemophilia diagnosis ) Documented medical history least 50 exposure day treatment factor VIII product Subject 's parent legally authorize representative provide informed consent Detectable inhibitor factor VIII measure screen sample local central hemostasis laboratory History inhibitor factor VIII time prior screen Subject one follow laboratory abnormality time screening : 1. platelet count &lt; 100,000/mm3 2. hemoglobin concentration &lt; 10 g/dL ( 100 g/L ) 3. serum creatinine &gt; 1.5 time ULN age 4. total bilirubin &gt; 2 time ULN age Subject inherit acquire hemostatic defect hemophilia A ( e.g. , platelet dysfunction secondary uremia , liver failure , von Willebrand 's Disease ) Subject know hypersensitivity RECOMBINATE rAHF Subject currently participate another investigational drug study participate clinical study involve investigational drug within 30 day study entry Subject identify investigator unable unwilling cooperate study procedure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Factor VIII Deficiency</keyword>
</DOC>